Cryogenx

UKI2S > Our Impact > Cryogenx

Introduction

As global temperatures rise – 700 million people are projected to be exposed to extreme heat by 2030 – so too does the danger of heatstroke – a deadly and fast-acting condition that can strike military personnel, frontline workers, and emergency responders alike. With traditional cooling methods falling short, new solutions are urgently needed.

Enter Cryogenx: a UK-based meditech company who have developed CGX1, a revolutionary, portable cooling system that treats heatstroke without the need for ice, refrigeration, or cold-chain logistics. Often described as a “defibrillator for heat,” the CGX1 delivers rapid, life-saving treatment in any environment, from the battlefield to construction sites, sports fields, and beyond.

Backed by a £430,000 investment from the UK Innovation & Science Seed Fund (UKI2S) as part of a £1.7 million seed round, Cryogenx is now driving FDA clearance and scaling up for global deployment.

The Science

Cryogenx’s CGX1 device offers an entirely new way to deliver critical care in extreme heat conditions. It works by rapidly reducing core body temperature in the field, stabilising patients in minutes without reliance on power-hungry cooling equipment or large infrastructure.

The technology is particularly vital for defence and emergency response teams, where on-the-move, high-intensity operations often push body temperatures beyond safe limits. By addressing the four environmental risk factors identified by the National Institute for Occupational Safety and Health – temperature, humidity, radiant heat, and wind speed – CGX1 gives frontline teams a portable, scalable tool to respond to heat-related illness, fast.

The Cryogenx product is also evolving. New modular versions of the technology are in development, alongside a subscription-based model to build long-term revenue.

UKI2S Impact

£430,000

UKI2S investment through the Defence and Security Seed portfolio (D2S)

£1.7 million

Total raised in seed round

1st of its kind

Portable, ice-free, life-saving cooling system in the UK market

Founder and CEO of Cryogenx: Matt Anderson

"Heatstroke isn’t just an isolated risk; it’s a rising global threat - and existing solutions simply aren’t practical enough to meet the challenge. We’ve designed CGX1 as a defibrillator for heatstroke, providing frontline responders and military personnel the ability to treat heat-related illness effectively, wherever it strikes. The backing from UKI2S is pivotal - it not only validates our mission but gives us the resources to accelerate regulatory clearance, scale manufacturing, and get this lifesaving technology into the hands of those who need it most."

UKI2S invested in Cryogenx through its Defence and Security Seed (D2S) portfolio, recognising the urgent need for innovation in the face of climate-driven health risks. Supporting them as they scale their impact and set a new benchmark for operational safety and resilience and ensuring this groundbreaking solution can be rapidly deployed where it’s needed most. With the potential to save lives and safeguard productivity, Cryogenx is exactly the kind of dual-use tech the UK needs right now.

As the world grapples with extreme heat and its impact on health, safety, and operations, Cryogenx is providing a bold, science-led answer. With CGX1 and future modular solutions, the company is redefining how we respond to one of the biggest emerging threats of our time – proving that with the right tech, we can keep cool under pressure.

© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.

The Science

UKI2S Impact

Founder and CEO of Cryogenx: Matt Anderson

Stay updated